BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9534866)

  • 1. Reduced myocardial cyclic GMP increases myocardial O2 consumption in control but not renal hypertension-induced cardiac hypertrophy.
    Sadoff JD; Scholz PM; Tse J; Weiss HR
    Cardiovasc Res; 1997 Dec; 36(3):453-9. PubMed ID: 9534866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative metabolic effects of cyclic GMP are altered in renal hypertension induced cardiac hypertrophy.
    Rabindranauth P; Naim KL; Scholz PM; Tse J; Sadoff JD; Weiss HR
    Basic Res Cardiol; 1997 Feb; 92(1):8-16. PubMed ID: 9062647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered relationship between cyclic GMP and myocardial O2 consumption in renal hypertension-induced cardiac hypertrophy.
    Rabindranauth P; Scholz PM; Tse J; Naim KL; Weiss HR
    Res Exp Med (Berl); 1998 Jul; 198(1):11-21. PubMed ID: 9706666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased O2 consumption and positive inotropy caused by cyclic GMP reduction are not altered after L-type calcium channel blockade.
    Leone RJ; Naim KL; Scholz PM; Weiss HR
    Pharmacology; 1998 Jan; 56(1):37-45. PubMed ID: 9467186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between cGMP and myocardial O2 consumption is altered in T4-induced cardiac hypertrophy.
    Weiss HR; Rodriguez E; Tse J
    Am J Physiol; 1995 Feb; 268(2 Pt 2):H686-91. PubMed ID: 7864195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts.
    Leone RJ; Straznicka M; Scholz PM; Weiss HR
    Basic Res Cardiol; 2000 Feb; 95(1):28-38. PubMed ID: 10752543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ethanol-induced reduction in myocardial oxygen consumption can be attenuated by inhibiting guanylyl cyclase.
    Lazar MJ; Patel K; Scholz PM; Weiss HR
    J Cardiovasc Pharmacol; 2001 Oct; 38(4):512-9. PubMed ID: 11588521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative metabolic and coronary flow effects of decreases in cAMP and increases in cGMP in control and renal hypertensive rabbit hearts.
    Rodriguez R; Molino B; Weiss HR; Scholz PM
    J Appl Physiol (1985); 2004 Jul; 97(1):439-45. PubMed ID: 14990553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Negative inotropic effects of C-type natriuretic peptide are attenuated in hypertrophied ventricular myocytes associated with reduced cyclic GMP production.
    Moalem J; Davidov T; Zhang Q; Grover GJ; Weiss HR; Scholz PM
    J Surg Res; 2006 Sep; 135(1):38-44. PubMed ID: 16600302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy.
    Straznicka M; Leone RJ; Scholz PM; Weiss HR
    J Surg Res; 1998 Apr; 76(1):61-6. PubMed ID: 9695741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial O2 supply and consumption in early cardiac hypertrophy of renal hypertensive rabbits.
    Cimini CM; Upsher ME; Weiss HR
    Basic Res Cardiol; 1989; 84(1):13-21. PubMed ID: 2522298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ageing blunts the effects of nitric oxide on myocardial O2 consumption.
    Weiss HR; Lazar MJ; Tse J; Scholz PM
    Clin Exp Pharmacol Physiol; 2002 Oct; 29(10):924-30. PubMed ID: 12207573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal muscarinic activity does not impede beta-adrenergic activation in rabbit hearts in controls or thyroxine-induced cardiac hypertrophy.
    Naim KL; Rabindranauth P; Scholz PM; Tse J; Weiss HR
    J Cardiovasc Pharmacol; 1997 Oct; 30(4):405-11. PubMed ID: 9335397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cGMP level that reduces cardiac myocyte O2 consumption is altered in renal hypertension.
    Straznicka M; Gong G; Tse J; Scholz PM; Weiss HR
    Am J Physiol; 1997 Oct; 273(4):H1949-55. PubMed ID: 9362265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts.
    Weiss HR; Rodriguez E; Tse J; Scholz PM
    Clin Exp Pharmacol Physiol; 1994 Aug; 21(8):607-14. PubMed ID: 7813120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in the level of cardiac cyclic GMP worsens contractile delay in myocardial stunning.
    Patel KN; Weiss HR; Scholz PM
    J Surg Res; 2000 Jul; 92(1):114-9. PubMed ID: 10864491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cyclic GMP reduction on regional myocardial mechanics and metabolism in experimental left ventricular hypertrophy.
    Guo X; Kedem J; Weiss HR; Tse J; Roitstein A; Scholz PM
    J Cardiovasc Pharmacol; 1996 Mar; 27(3):392-400. PubMed ID: 8907801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes.
    Straznicka M; Gong G; Yan L; Scholz PM; Weiss HR
    J Cardiovasc Pharmacol; 1999 Aug; 34(2):229-36. PubMed ID: 10445674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic nitric oxide synthase blockade desensitizes the heart to the negative metabolic effects of nitric oxide.
    Davidov T; Weiss HR; Tse J; Scholz PM
    Life Sci; 2006 Sep; 79(17):1674-80. PubMed ID: 16831448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guanylyl cyclase inhibition reduces contractility and decreases cGMP and cAMP in isolated rat hearts.
    Klabunde RE; Tse J; Weiss HR
    Cardiovasc Res; 1998 Mar; 37(3):676-83. PubMed ID: 9659451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.